Trials / Completed
CompletedNCT06690242
MT1013 Injection for the Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease
A Multicenter, Randomized,Positive Controlled, and Placebo-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of MT1013 Injection in Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism Undergoing Maintenance Hemodialysis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 115 (actual)
- Sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, positive controlled, and placebo-controlled phase II clinical study to evaluate the efficacy and safety of MT1013 injection in the treatment of chronic kidney disease with secondary hyperparathyroidism (SHPT) undergoing maintenance hemodialysis (MHD) subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MT1013 | MT1013 is a novel calcimimetic agent |
| DRUG | MT1013 | MT1013 is a novel calcimimetic agent |
| DRUG | Etelcalcetide Hydrochloride | the already-marketed therapeutic agents |
| DRUG | Placebo | The measure does not contain the active ingredients |
Timeline
- Start date
- 2024-11-04
- Primary completion
- 2025-10-15
- Completion
- 2025-10-15
- First posted
- 2024-11-15
- Last updated
- 2026-02-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06690242. Inclusion in this directory is not an endorsement.